Breaking News

Capsida, KateTx Enter Strategic Mfg. Alliance for Gene Therapies

Leverages Capsida's next-gen manufacturing capabilities to enable development of KateTx's gene therapies for muscle and heart diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Capsida Biotherapeutics Inc. and Kate Therapeutics (KateTx) entered a strategic partnership to leverage Capsida’s adeno-associated virus (AAV) manufacturing capabilities to enable KateTx’s initial internal portfolio of muscle and heart disease programs.   Capsida will provide GMP manufacturing of KateTx’s gene therapies as the medicines advance through preclinical and clinical development. Capsida will receive funding for the term of the agreement.   KateTx’s internal...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters